Shares of Genelux Co. (NASDAQ:GNLX – Get Free Report) dropped 1.3% on Friday . The stock traded as low as $3.76 and last traded at $3.93. Approximately 93,061 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 199,940 shares. The stock had previously closed at $3.98.
Genelux Trading Down 1.3 %
The stock has a market cap of $135.73 million, a P/E ratio of -4.14 and a beta of -1.41. The stock’s 50-day moving average is $3.97 and its 200-day moving average is $3.07.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP lifted its position in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after purchasing an additional 52,958 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Genelux during the 4th quarter valued at $41,000. LPL Financial LLC raised its stake in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after buying an additional 39,516 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Genelux in the fourth quarter valued at $25,000. Finally, LifeSteps Financial Inc. boosted its stake in Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after buying an additional 8,715 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Genelux
- 3 Best Fintech Stocks for a Portfolio Boost
- FedEx Delivers Another Crushing Blow to Its Stock Price
- Insider Trades May Not Tell You What You Think
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What is a buyback in stocks? A comprehensive guide for investors
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
